Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast Limited has notified the market that 10,228,239 ordinary shares currently subject to voluntary escrow arrangements will be released on 8 January 2026, in line with ASX Listing Rule 3.10A disclosure requirements. The impending release of these escrowed shares will increase the tradable free float of Mesoblast’s stock, which may influence liquidity and shareholding dynamics for existing and prospective investors.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited (ASX: MSB) is an Australia-listed biotechnology company; the release does not provide additional details on its specific products, services, or therapeutic focus areas.
Average Trading Volume: 4,763,383
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$3.72B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.